Resting heart rate and incident heart failure and cardiovascular mortality in older adults: Role of inflammation and endothelial dysfunction: The PROSPER study

European Journal of Heart Failure

Volumn 15, Issue 5, 2013, Pages 581-588

  Nanchen, David ^a,b   Stott, David J ^c   Gussekloo, Jacobijn ^b   Mooijaart, Simon P ^b,d   Westendorp, Rudi G J ^b   Jukema, J Wouter ^b   MacFarlane, Peter W ^c   Cornuz, Jacques ^a   Rodondi, Nicolas ^e   Buckley, Brendan M ^f   Ford, Ian ^c   Sattar, Naveed ^c   De Craen, Anton J M ^b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d Institute for Evidence Based Medicine in Old Age   (Netherlands)

^e UNIVERSITY OF BERN   (Switzerland)

^f University College Cork and INFANT Centre   (Ireland)

Author keywords

Cardiovascular; Endothelium; Geriatrics; Heart rate; Inflammation; Prevention screening

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; PRAVASTATIN; THYROID HORMONE; THYROTROPIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

AGED; ALCOHOL CONSUMPTION; ANGINA PECTORIS; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; CORRELATIONAL STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DRUG USE; ENDOTHELIAL DYSFUNCTION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART RATE; HOSPITALIZATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REST; SECONDARY PREVENTION; SMOKING; SYSTOLIC BLOOD PRESSURE; THYROTROPIN BLOOD LEVEL; TRANSIENT ISCHEMIC ATTACK; TRIACYLGLYCEROL BLOOD LEVEL;

AGE FACTORS; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART RATE; HOSPITALIZATION; HUMANS; INCIDENCE; INFLAMMATION; INTERLEUKIN-6; MALE; PROSPECTIVE STUDIES; RISK FACTORS; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

EID: 84877135139     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfs195     Document Type: Article

References (27)

1. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967-974.
2. Kannel WB, Kannel C, Paffenbarger RS, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987; 113: 1489-1494.
3. Fox KM, Ferrari R. Heart rate: a forgotten link in coronary artery disease? Nat Rev Cardiol 2011; 8: 369-379.
4. de Ruijter W, Westendorp RG, Assendelft WJ, den Elzen WP, de Craen AJ, le Cessie S, Gussekloo J. Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ 2009; 338: a3083.
5. Custodis F, Schirmer SH, Baumha?kel M, Heusch G, Bo?hm M, Laufs U. Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol 2010; 56: 1973-1983.
6. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
7. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011; 17: 1410-1422.
8. Lampert R, Bremner JD, Su S, Miller A, Lee F, Cheema F, Goldberg J, Vaccarino V. Decreased heart rate variability is associated with higher levels of inflammation in middle-aged men. Am Heart J 2008; 156: e751-e757.
9. Rogowski O, Shapira I, Shirom A, Melamed S, Toker S, Berliner S. Heart rate and microinflammation in men: a relevant atherothrombotic link. Heart 2007; 93: 940-944.
10. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004; 109: II27-II33.
11. Brotman DJ, Bash LD, Qayyum R, Crews D, Whitsel EA, Astor BC, Coresh J. Heart rate variability predicts ESRD and CKD-related hospitalization. J Am Soc Nephrol 2010; 21: 1560-1570.
12. Sajadieh A, Nielsen OW, Rasmussen V, Hein HO, Hansen JF. C-reactive protein, heart rate variability and prognosis in community subjects with no apparent heart disease. J Intern Med 2006; 260: 377-387.
13. Jensen MT, Marott JL, Allin KH, Nordestgaard BG, Jensen GB. Resting heart rate is associated with cardiovascular and all-cause mortality after adjusting for inflammatory markers: the Copenhagen City Heart Study. Eur J Prev Cardiol 2012; 19: 102-108.
14. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-1630.
15. Shepherd J, Blauw GJ, Murphy MB, Cobbe SM, Bollen ELEM, Buckley BM, Ford I, Jukema JW, Hyland M, Gaw A, Lagaay AM, Perry IJ, Macfarlane PW, Meinders AE, Sweeney BJ, Packard CJ, Westendorp RGJ, Twomey C, Stott DJ. The design of a prospective study of pravastatin in the elderly at risk (PROSPER). Am J Cardiol 1999; 84: 1192-1197.
16. Macfarlane PW, Murray H, Sattar N, Stott DJ, Ford I, Buckley B, Jukema JW, Westendorp RGJ, Shepherd J. The incidence and risk factors for new onset atrial fibrillation in the PROSPER study. Europace 2011; 13: 634-639.
17. Sattar N, Murray HM, Welsh P, Blauw GJ, Buckley BM, Cobbe S, de Craen AJ, Lowe GD, Jukema JW, Macfarlane PW, Murphy MB, Stott DJ, Westendorp RG, Shepherd J, Ford I, Packard CJ. Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events? PLoS Med 2009; 6: e1000099.
18. Stott DJ, Robertson M, Rumley A, Welsh P, Sattar N, Packard CJ, Shepherd J, Trompet S, Westendorp RG, de Craen AJ, Jukema JW, Buckley B, Ford I, Lowe GD. Activation of hemostasis and decline in cognitive function in older people. Arterioscler Thromb Vasc Biol 2010; 30: 605-611.
19. Ford I, Bezlyak V, Stott DJ, Sattar N, Packard CJ, Perry I, Buckley BM, Jukema JW, de Craen AJ, Westendorp RG, Shepherd J. Reduced glomerular filtration rate and its association with clinical outcome in older patients at risk of vascular events: secondary analysis. PLoS Med 2009; 6: e16.
20. Nanchen D, Gussekloo J, Westendorp RG, Stott DJ, Jukema JW, Trompet S, Ford I, Welsh P, Sattar N, Macfarlane PW, Mooijaart SP, Rodondi N, de Craen AJ. Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk. J Clin Endocrinol Metab 2012; 97: 852-861.
21. Bonnemeier H, Richardt G, Potratz J, Wiegand UK, Brandes A, Kluge N, Katus HA. Circadian profile of cardiac autonomic nervous modulation in healthy subjects: differing effects of aging and gender on heart rate variability. J Cardiovasc Electrophysiol 2003; 14: 791-799.
22. Lowe GDO, Danesh J, Lewington S, Walker M, Lennon L, Thomson A, Rumley A, Whincup PH. Tissue plasminogen activator antigen and coronary heart disease. Eur Heart J 2004; 25: 252-259.
23. van Galen KPM, Tuinenburg A, Smeets EM, Schutgens REG. Von Willebrand factor deficiency and atherosclerosis. Blood Rev 2012; 26: 189-196.
24. Papadaki M, Ruef J, Nguyen KT, Li F, Patterson C, Eskin SG, McIntire LV, Runge MS. Differential regulation of protease activated receptor-1 and tissue plasminogen activator expression by shear stress in vascular smooth muscle cells. Circ Res 1998; 83: 1027-1034.
25. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-885.
26. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 807-816.
27. Herring N, Lee CW, Sunderland N, Wright K, Paterson DJ. Pravastatin normalises peripheral cardiac sympathetic hyperactivity in the spontaneously hypertensive rat. J Mol Cell Cardiol 2011; 50: 99-106.